Nootropic · 60mg × 6 vials
it is a complex of pig-brain-derived peptide fragments that act like the brain's own growth factors to push damaged neurons toward repair and to support plasticity in healthy ones.
Cerebrolysin is a porcine brain-derived peptide preparation made by EVER Pharma (Austria) via standardized enzymatic breakdown of pig brain tissue into a defined mixture of low-molecular-weight neuropeptides (under 10 kDa) plus free amino acids. It is not a single molecule. The active fraction is a complex of small peptides that act as exogenous mimics of the brain's own neurotrophic factors, principally BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), CNTF (ciliary neurotrophic factor), and GDNF (glial-derived neurotrophic factor). Because these mimics are short peptide fragments rather than the full-length proteins, they can cross the blood-brain barrier where the parent neurotrophins cannot. Once across, they trigger TrkB and TrkA receptor signaling, drive neurogenesis in the hippocampus and subventricular zone, support synaptic plasticity, reduce excitotoxic injury (modulating glutamate/NMDA pathways), inhibit apoptosis in stressed neurons, and stabilize the blood-brain barrier itself. The net result documented across 40+ years of mostly Eastern European clinical use is acceleration of post-injury neuronal recovery: ischemic stroke, traumatic brain injury, vascular dementia, and Alzheimer's-type cognitive decline. In plain language: it is a complex of pig-brain-derived peptide fragments that act like the brain's own growth factors to push damaged neurons toward repair and to support plasticity in healthy ones. It is the most-studied neurotrophic-mimetic compound in clinical medicine outside of standard-of-care neurology, with most of the published trial evidence concentrated in Russia, Ukraine, Austria, Germany, China, and India.
Typical dose ranges by experience level - educational reference. Message us and we tailor it to you.
For healthy adults running Cerebrolysin as a cognitive/neuroprotective course rather than for acute injury, 1 ampule per day for 10 consecutive days is the standard starting protocol. Subjective effects (mental clarity, mood lift, sleep quality) are subtle and build across the back half of the course rather than hitting on day one. Most beginners feel something by day 5-7. The 6 vial PP kit (CBL60) is sized for slightly more than half a 10 day starter course, customers running a full 10 day course typically order 2 kits.
This is the dosing band for early/mild cognitive decline, post-concussion recovery (1-12 months post-injury), long-covid cognitive symptoms that have not responded to Semax/NAD+, and as the maintenance band for stroke recovery customers past the acute window. Three CBL60 kits cover a full 20 day intermediate course at 2 ampules/day.
Advanced IM dosing is used in research contexts for moderate-to-severe Alzheimer's, vascular dementia, post-stroke deficits beyond the 6-month window, and TBI recovery in the 1-12 month post-injury range. The CARS and CASTA stroke trials and the Alvarez Alzheimer's trials are the published reference points. For PP customers, advanced dosing is almost always either family-of-stroke-patient research scenarios or post-TBI recovery, not casual nootropic use. Pair with Semax intranasal across the same course for the canonical Russian post-stroke stack.
Straight talk - what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines - tap any to read the source.
Cerebrolysin Acute Stroke Treatment in Asia, 1070 patients, randomized double-blind placebo-controlled, IV 30 mL/day × 10 days
Read study ↗PubMedMuresanu et al, CARS trial - Cerebrolysin in early post-stroke rehabilitationCerebrolysin and Recovery After Stroke, 208 patients, motor function recovery
Read study ↗PubMedAlvarez et al, Cerebrolysin in mild-to-moderate Alzheimer's diseaserandomized double-blind placebo-controlled, cognitive and global outcome improvement at 24 weeks
Read study ↗PubMedBornstein et al, Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysispooled analysis across nine RCTs
Read study ↗PubMedChen et al, Cerebrolysin in TBI - randomized clinical trialtraumatic brain injury, cognitive outcomes at 30 and 90 days
Read study ↗PubMedPlosker GL, Gauthier S, Cerebrolysin: a review in vascular dementia and Alzheimer's diseasecomprehensive pharmacology and clinical review
Read study ↗Aggregated sentiment from public forums & socials - real-world reports, not individual endorsements.
Injection sting during IM push: most-reported sensation, manageable by injecting slowly over 10-15 seconds and room-temping the ampule first
Mental clarity / cognitive lift: build is subtle, most users report noticing something around day 5-7 of a daily course rather than immediate effect
Mood lift: commonly reported, described as "lighter" or "less depressed" rather than euphoric
Sleep quality improvement: occasionally reported, especially in customers running it for post-concussion or general cognitive decline
Mild fatigue first 2-3 days of a course: occasionally reported, resolves as the course continues
Vivid dreams: occasionally reported, generally regarded as neutral or pleasant
Route: IM (intramuscular) for community/research dosing; IV infusion for in-hospital acute stroke and TBI protocols
Injection site: deep IM into outer thigh (vastus lateralis) or gluteal muscle, 23-25g needle for IM draw, 1-1.5 inch needle for deep IM. Rotate sites across the course.
Storage: pre-loaded ampules, refrigerated 2-8°C, manufacturer shelf life 4-5 years sealed. Once an ampule is opened, use immediately and discard the remainder, do not store opened ampules.
Notes: Inject slowly over 10-15 seconds, IM Cerebrolysin can sting/burn during push if given too fast. Room-temp the ampule by holding in hand for 1-2 min before injection to reduce sting. Light amber color is normal, discard any ampule that has turned cloudy or dark brown. Course is daily injection for 10-30 consecutive days, NOT once-weekly. The single most common admin mistake is treating Cerebrolysin like a typical research peptide and dosing 2-3× per week, the published efficacy is built on consecutive-day courses.